<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103050</url>
  </required_header>
  <id_info>
    <org_study_id>CQAV680A2204</org_study_id>
    <nct_id>NCT01103050</nct_id>
  </id_info>
  <brief_title>A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Placebo Controlled Three-period Incomplete Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine on Total Nasal Symptom Score in Allergic Rhinitis Patients in an Environmental Exposure Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will determine the capacity of more frequent dosing of QAV680 to suppress allergic
      inflammation. The study will investigate the paradigm of multiple receptor antagonism in
      allergic disease by combining QAV680 with a second generation H1 histamine receptor
      antagonist to assess possible additive or synergistic anti-allergic effects of the two
      compound classes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2010</start_date>
  <completion_date type="Actual">July 28, 2010</completion_date>
  <primary_completion_date type="Actual">July 28, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Nasal Symptom Score measured during allergen exposure</measure>
    <time_frame>14 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal airway patency assessed by acoustic rhinometry during allergen exposure</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal secretion weight during allergen exposure</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Nasal Symptom Score &amp; Total Ocular Symptom Score measured during allergen exposure</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>QAV680 + Cetirizine Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAV680 + Cetirizine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetirizine + QAV680 Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAV680 Placebo + Cetirizine Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAV680 + Cetirizine Placebo</intervention_name>
    <arm_group_label>QAV680 + Cetirizine Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAV680 + Cetirizine</intervention_name>
    <arm_group_label>QAV680 + Cetirizine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine + QAV680 Placebo</intervention_name>
    <arm_group_label>Cetirizine + QAV680 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAV680 Placebo + Cetirizine Placebo</intervention_name>
    <arm_group_label>QAV680 Placebo + Cetirizine Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical history of intermittent allergic rhinitis with seasonal onset
             and offset of nasal allergy symptoms during each of the last two ragweed allergy
             seasons

          -  positive skin prick test to ragweed allergen within twelve months of screening

        Exclusion criteria:

          -  Use of any medication used to treat allergy (administered via any route), such as:
             pseudoephedrine, antihistamines, ipratropium bromide, cromoglycates, corticosteroids,
             immunotherapy or other antiinflammatory or immunosuppressive agents, or any other
             medication administered via the nasal or ocular routes)

          -  Within the last three years a recurrent history of acute or chronic bronchospastic
             disease including moderate-severe asthma or chronic obstructive pulmonary disease

          -  Nasal conditions such as nasal septal perforations,nasal polyps, sinus disease,
             chronic nasal obstruction

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4660</url>
    <description>Results for CQAV680A2204 from the Novartis Clinical Trials Website</description>
  </link>
  <link>
    <url>http://www.ers-education.org/home/browse-all-content.aspx?idParent=136559</url>
    <description>Publication Link QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic inflammation</keyword>
  <keyword>Seasonal rhinitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

